San Diego, CA -- (SBWIRE) -- 03/03/2017 -- Momenta Pharmaceuticals, Inc is under investigation over potential securities laws violations. The investigation was announced for investors in NASDAQ:MNTA shares in connection certain financial statements made by Momenta Pharmaceuticals, Inc.

Investors who purchased shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on whether a series of statements by Momenta Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On February 17, 2017, Momenta Pharmaceuticals, Inc. disclosed that a contracted Pfizer facility used to manufacture the Company's Glatopa product had received a warning letter from the U.S. Food and Drug Administration ("FDA"). Momenta Pharmaceuticals, Inc's Abbreviated New Drug Application for its Glatopa 40 mg product candidate remains under regulatory review, and under FDA policy, final approval is dependent on the satisfactory resolution of the compliance observations at the Pfizer manufacturing facility. Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) declined on February 21 2017 to as low as $14.42 per share.

On March 2, 2017, NASDAQ:MNTA shares closed at $14.80 per share.

Those who purchased shares of Momenta Pharmaceuticals, Inc. have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com